Breaking News

MannKind Ends Afrezza License with Sanofi

January 5, 2016

Will transition development and commercialization to MannKind

MannKind Corp. has terminated its license and collaboration agreement with Sanofi-aventis U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The companies will transition the development and commercialization of Afrezza from Sanofi to MannKind within 180 days.
 
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the Sanofi collaboration.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems